ReutersClovis's ovarian cancer drug set for label expansion, shares soar

Jun 19, 2017 - Health

Related media:

n"Positive late-stage data on Clovis Oncology Inc's ovarian cancer drug, Rubraca, could help widen the use of the therapy and differentiate it from rivals, the U.S. biotech said on Monday, sending its shares soaring 48 percent.The drug, like Tesaro Inc's Zejula and AstraZeneca Plc's Lynparza, belongs to a closely watched class of new medicines called PARP inhibitors, which blocks enzymes that repair damaged DNA, helping kill cancer cells in the process.Tesaro's shares fell about 16.8...

Read the story on Reuters.

Related stories

  • Reuters Novartis throws down gauntlet to Roche with Rituxan copy

    Jun 19, 2017

    ZURICH Switzerland’s Novartis increased pressure on Roche’s ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.Rixathon, from Novartis’s Sandoz generics unit, follows Celltrion’s Truxima that secured the European Commission’s blessing in February to be used against diseases including non-Hodgkin’s lymphoma and Read more...

  • The San Diego Union-Tribune Biotechs find stability despite turbulence, new study finds

    Jun 19, 2017

    In its relatively brief lifetime, the biotechnology industry has swung between exuberance and despondency. In an uncertain environment, the best path is to stay the course, according to a new report from the professional services firm EY.To stay the course means continuing to invest in new technologies, trusting in “the long development cycles of biotech” to provide return on investment Read more...

  • The San Diego Union-Tribune Backstory to the 2017 biotech convention in San Diego

    Jun 19, 2017

    Today’s Backstory features Bradley J. Fikes, who writes about biotechnology and life science for The San Diego Union-Tribune.His article about some of the hottest fields in the life sciences appears on the front page of Sunday’s print edition. It’s timed to the start of the BIO convention, the world’s largest biotech gathering, which will take place this week at the Read more...

More stories ...

Related videos

  • , title : 'Clovis Oncology Announces FDA Accelerated Approval of RUBRACA™ ...'
    Clovis Oncology Announces FDA Accelerated Approval of RUBRACA™ ...
    (rucaparib) for the Monotherapy Treatment of Advanced Ovarian Cancer in Women with Deleterious Germline or Somatic BRCA Mutations... Rubraca Clinician ...
  • , title : 'Clovis Oncology Announces FDA Accelerated Approval of RUBRACA™ ...'
    Clovis Oncology Announces FDA Accelerated Approval of RUBRACA™ ...
    (rucaparib) for the Monotherapy Treatment of Advanced Ovarian Cancer in Women with Deleterious Germline or Somatic BRCA Mutations... Rubraca Patient ...
  • , title : 'LIVE - Floor of the NYSE! June 23, 2017 Financial News - Business News - Stock News - Market News'
    LIVE - Floor of the NYSE! June 23, 2017 Financial News - Business News - Stock News - Market News
    Watch Us LIVE from the Floor of NYSE! June 23, 2017 Financial News - Business News - Stock News - Market News - Stock Exchange CLICK HERE➡ ...

Related tweets

Clovis's ovarian cancer drug set for label expansion, shares soar - Reuters ift.tt/2rEuQ3R via Black Swan Intelligent Insight™

#Clovis's ovarian cancer #drug set for label expansion shares soar @PharmaCompass goo.gl/oa1gtk

test Twitter Media - #Clovis's ovarian cancer #drug set for label expansion  shares soar
@PharmaCompass
https://t.co/JvI0ygEAOr https://t.co/p07pT3e1Eu

Clovis's ovarian cancer drug set for label expansion, shares soar - Reuters ift.tt/2tM3hq9 via Black Swan Intelligent Insight™